Immunogen Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.39
Dividend & YieldN/A$ (N/A)
Beta 1.06
Market capitalization 1.11B
Operating cash flow -215.48M
ESG Scores unknown

Company description

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities -6.5M 45.59M -18.14M -8.89M
Total Cashflows From Investing Activities -5.25M -533k 509k -1.43M
Net Borrowings -1.1M -1.1M -1.1M -1.1M
Total Cash From Financing Activities 166.81M 2.87M 195.74M 355.74M
Change To Operating Activities 2.75M -10.55M 1.5M -4.89M
Issuance Of Stock 167.21M 2.87M 196.44M 158.17M
Net Income -168.84M -104.13M -44.37M -139.3M
Change In Cash -4.86M -86.03M 117.63M 184.89M
Effect Of Exchange Rate
Total Cash From Operating Activities -166.42M -88.37M -78.62M -169.42M
Depreciation 7.41M 4.03M 2.1M 2.02M
Change To Account Receivables 2.41M -9.31M 12.09M -9.77M
Other Cashflows From Financing Activities -395k -701k -701k 198.67M
Change To Netincome -4.7M -13.99M -31.79M -8.58M
Capital Expenditures -5.25M -2.85M -917k -1.43M

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development
Income Before Tax -168.84M -104.13M -44.37M -139.3M
Net Income -168.84M -104.13M -44.37M -139.3M
Selling General Administrative 36.75M 38.49M 38.6M 43.81M
Gross Profit -121.01M -32.25M 17.71M -81.26M
Ebit -157.76M -70.74M -20.89M -125.07M
Operating Income -157.76M -70.74M -20.89M -125.07M
Interest Expense -10.73M -16.97M -23.2M -13.15M
Income Tax Expense
Total Revenue 53.45M 82.27M 132.3M 69.86M
Cost Of Revenue 174.46M 114.52M 114.59M 151.12M
Total Other Income ExpenseNet -11.09M -33.39M -23.48M -14.23M
Net Income From Continuing Ops -168.84M -104.13M -44.37M -139.3M
Net Income Applicable To Common Shares -168.84M -104.13M -44.37M -139.3M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 284.41M 311.38M 265.5M 200.18M
Total Stockholder Equity 10.97M -76.12M 89.57M 325.59M
Other Current Liabilities 27.03M 41.58M 73.61M 50.43M
Total Assets 295.38M 235.26M 355.07M 525.76M
Common Stock 1.49M 1.5M 1.95M 2.2M
Other Current Assets
Retained Earnings -1.18B -1.29B -1.33B -1.47B
Treasury Stock
Cash 262.25M 176.22M 293.86M 478.75M
Total Current Liabilities 70.66M 77.41M 122.32M 100.94M
Other Stockholder Equity
Property, Plant, and Equipment 12.89M 22.58M 19.83M 17.05M
Total Current Assets 278.78M 208.9M 324.25M 500M
Net Tangible Assets 10.97M -76.12M 89.57M 325.59M
Net Receivables 12.07M 27.25M 22.5M 13.93M
Accounts Payable 11.37M 9.93M 9.54M 18.43M


Insider Transactions

Here are the insider transactions of stock shares related to Immunogen Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
HARRINGTON-SMITH KRISTEND2022-11-15Officer25k
WINGROVE THERESA GStock Award(Grant) at price 3.83 per share.D2022-06-30Officer2.65k
ENYEDY MARK JStock Award(Grant) at price 3.83 per share.D2022-06-30Chief Executive Officer3.34k
BERKENBLIT ANNAStock Award(Grant) at price 3.83 per share.D2022-06-30Officer3.07k
COEN STACY ANNStock Award(Grant) at price 3.83 per share.D2022-06-30Officer3.34k
LENTINI RENEEStock Award(Grant) at price 3.83 per share.D2022-06-30Officer2.51k
WINGROVE THERESA GStock Award(Grant) at price 7.42 per share.D2021-12-31Officer2.05k
BERKENBLIT ANNAStock Award(Grant) at price 7.42 per share.D2021-12-31Officer1.76k
COEN STACY ANNStock Award(Grant) at price 7.42 per share.D2021-12-31Officer1.5k
LENTINI RENEEStock Award(Grant) at price 7.42 per share.D2021-12-31Officer1.96k
MITCHELL DEAN JConversion of Exercise of derivative security at price 1.84 - 4.64 per share.D2021-09-03Director83k
WINGROVE THERESA GStock Award(Grant) at price 5.52 per share.D2021-06-30Officer1.77k
ENYEDY MARK JStock Award(Grant) at price 5.52 per share.D2021-06-30Chief Executive Officer3.85k
BERKENBLIT ANNAStock Award(Grant) at price 5.52 per share.D2021-06-30Officer2.06k
RYLL THOMASStock Award(Grant) at price 5.52 per share.D2021-06-30Officer3.85k
COEN STACY ANNStock Award(Grant) at price 5.52 per share.D2021-06-30Officer2.33k
LENTINI RENEEStock Award(Grant) at price 5.52 per share.D2021-06-30Officer1.68k
FOSTER DAVID GSale at price 6.38 per share.D2020-12-31Officer11.05k
FOSTER DAVID GD2020-12-31Officer27.24k
FOSTER DAVID GStock Award(Grant) at price 6.45 per share.D2020-12-31Officer362
WINGROVE THERESA GStock Award(Grant) at price 6.45 per share.D2020-12-31Officer2.66k
BERKENBLIT ANNAStock Award(Grant) at price 6.45 per share.D2020-12-31Officer2.2k
ENYEDY MARK JStock Gift at price 0.00 per share.D2020-12-22Chief Executive Officer10k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to Immunogen Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on Immunogen Inc

Here is the result of two systematic investment strategies applied to Immunogen Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on Immunogen Inc

The following chart shows the equity curve of the two systematic investment strategies applied to Immunogen Inc:

Immunogen Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 54.43% on the backtest period.

Performance at glance

Performance

54.43 %

Latent gain

957.87 $

Invested capital

1759.67 $

Annualized return

13.28 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on Immunogen Inc

This is the result of two momentum investment strategies applied to Immunogen Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on Immunogen Inc

The following chart shows all the entries opened by the momentum investment system on Immunogen Inc:

Immunogen Inc momentum entries
  • The first momentum investment strategy would give 41.34% of return on Immunogen Inc. That represents 2170.98$ of latent gain with 5251.26$ of employed capital.
  • The second momentum investment strategy would give 49.63% of return on Immunogen Inc. That represents 1368.41$ of latent gain with 2757.25$ of employed capital.
Performance at glance (1Q Momentum)

Performance

41.34 %

Latent gain

2170.98 $

Invested capital

5251.26 $

Annualized return

6.5 %
Performance at glance (2Q Momentum)

Performance

49.63 %

Latent gain

1368.41 $

Invested capital

2757.25 $

Annualized return

13.71 %

Momentum equity curve on Immunogen Inc

The following chart shows the equity curve of the two momentum strategies applied to Immunogen Inc:

Immunogen Inc momentum equity

Note: the dividends potentially given by Immunogen Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Immunogen Inc

The following chart shows the employed capital evolution of the two momentum strategies on Immunogen Inc since the beginning:

Immunogen Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on Immunogen Inc

Buy the dip entry openings on Immunogen Inc

Immunogen Inc

The performance achieved by the robo-advisor on Immunogen Inc is 13.64%. That represents 33.97$ of latent gain with 248.97$ of employed capital. The following chart shows Immunogen Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of Immunogen Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

13.64 %

Latent gain

33.97 $

Invested capital

248.97 $

Annualized return

6.5 %

Equity curve of the strategy applied to Immunogen Inc

The following chart shows the result of the investment strategy applied to Immunogen Inc:

Immunogen Inc

Note: the dividends potentially given by Immunogen Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on Immunogen Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on Immunogen Inc:

Immunogen Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on Immunogen Inc

In this section, I will compare the three previous investment strategies applied to Immunogen Inc.

Equity curve comparison on Immunogen Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

Immunogen Inc investment strategy comparison

Employed capital comparison on Immunogen Inc

Immunogen Inc investment comparison

Performance comparison on Immunogen Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 54.43% 957.87$ 1759.67$ 13.28%
Momentum 1 quarter 41.34% 2170.98$ 5251.26$ 10.71%
Momentum 2 quarters 49.63% 1368.41$ 2757.25$ 13.71%
Non-directional 13.64% 33.97$ 248.97$ 6.5%
Annualized return comparison

Automatic investment

13.28 %

Momentum 1Q

13.71 %

Momentum 2Q

13.71 %

Non-directional

6.5 %

Correlated stocks

Here are the most positively and negatively correlated stocks with Immunogen Inc:

Positive correlations

Most correlated stocks this year

  • Immunogen Inc

  • Most correlated stocks last 3 months

  • MELBOURNE ENT
  • Immunogen Inc
  • MODERN LIVING
  • UNI MEDICAL

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • iShares MSCI Global Agriculture Producers ETF

  • Note: The algorithm computes the probability of correlation between Immunogen Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of Immunogen Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name Immunogen Inc
    Country United States
    City Waltham
    Address 830 Winter Street
    Phone 781 895 0600
    Website www.immunogen.com
    FullTime employees 106
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker IMGN
    Market www.nasdaq.com

    Immunogen Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown